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A great deal of circumstantial evidence has linked iodine with the rising incidence of autoimmune
thyroiditis in the United States. In our investigations, we have shown directly that T cells from
humans with chronic lymphocytic thyroiditis proliferate in the presence of iodinated but not in the
presence of noniodinated human thyroglobulin. Moreover, the proliferative response is restored
when the thyroglobulin is iodinated artificially in vitro. Using a panel of monoclonal antibodies, we
found evidence that the presence of iodine induces a number of stereochemical changes in the
conformation of the molecule, resulting in the loss of some antigenic determinants and the
appearance of others. One prominent determinant was associated with the iodine-containing amino
acid thyroxine. Both the number and position of the iodine substituents determine the precise
specificity of this epitope. A new model for the study of the role of iodine in inducing thyroid
autoimmunity has become available in the form of the nonobese diabetic (NOD)-H2h4 mouse. This
animal develops autoimmune thyroiditis spontaneously but in relatively low prevalence. However, if
iodine is added to the drinking water, the prevalence and severity of the thyroid lesions increase
markedly. The immune response is specific for thyroglobulin, both in terms of the antibody
response and T-cell proliferation. In fact, the appearance of lesions can be predicted by the
presence of thyroglobulin-specific IgG2b antibody. The disease, moreover, can be transferred
adoptively, using spleen cells from iodine-fed donors treated in vitro with iodinated thyroglobulin.
The effects of iodine feeding are greater in conventional animals compared with those maintained
under specific pathogen-free conditions. Based on T-cell proliferation, it appears that the NOD-H2h4
strain of mice has innately a greater response to murine thyroglobulin than do other mouse strains
and that the proliferation is increased even more by feeding iodine. We suggest, therefore, that the
presence of iodine increases the autoantigenic potency of thyroglobulin, a major pathogenic antigen
in the induction of autoimmune thyroiditis. This animal model provides a unique opportunity for
investigating in detail the mechanisms by which an environmental agent can trigger a pathogenic
autoimmune response in a susceptible host. Key words: autoimmune disease, autoimmunity,
iodine, thyroglobulin, thyroiditis, thyronine, thyroxine, tyrosine. - Environ Health Perspect 107(suppl
5):749-752 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/suppl-5/749-752rose/abstract.html
Autoimmune Disease Is a
Public Health Problem in the
United States
The autoimmune diseases collectively represent
a significant cause ofchronic morbidity and
disability in the United States. Unfortunately,
few studies have measured quantitatively the
impact of these diseases on the American
population. Part of the problem is because
autoimmunity as a major cause ofhuman dis-
ease is a relatively recent discovery and very
few agencies have concerned themselves with
the autoimmune diseases as a group. Because
autoimmune disease can affect virtually any
organ ofthe body, its manifestations are pro-
tean. Autoimmune diseases therefore tend to
be treated by physicians from many different
specialties (1). Yet, because they are all linked
by their etiology, it is important to consider
them as a group when assessing the popula-
tional burden.
In a recent analysis, we estimated the
number of persons affected by 24 well-
established autoimmune diseases in the
United States by applying mean weighted
prevalence rates (2). The study was restricted
to those diseases with well-defined evidence
for an autoimmune pathogenicity and for
which well-documented epidemiologic studies
had been reported. Overall, we were able to
estimate that approximately 8.5 million per-
sons in the United States, or 1/31 Americans,
are currently afflicted by one ofthe autoim-
mune disorders. The diseases with the highest
prevalence rates are Graves disease (estimated
prevalence 1,151.5/100,000); rheumatoid
arthritis (estimated prevalence 860/100,000);
and chronic lymphocytic thyroiditis
(estimated prevalence 791.65/100,000).
Moreover, it is evident that the occurrence of
many ofthe autoimmune diseases is rising,
although it is unclear whether it is due to
greaterrecognition or an increasedprevalence.
Genetic Predisposition and
Environmental Triggers
One of the characteristics common to all
autoimmune diseases is theclusteringofseveral
diseases with an autoimmune origin in the
same individual or in family members.
Although this clustering can be taken as prima
facie evidence of a genetic predisposition,
formal proofrests upon the demonstration of
genetic determination ofwell-defined autoim-
mune diseases in animals. The first instance of
clear genetic control was the demonstration
that susceptibility to experimental thyroiditis
in mice is associated with the H-2 haplotype
(3). This study engendered many other inves-
tigations of animal models showing an
enhanced susceptibility to several autoimmune
diseases related to the class II major histocom-
patibility complex (MHC) determinants (4).
Large-scale parallel investigations ofhuman
populations showed that many autoimmune
diseases have marked predilection for certain
human leukocyte antigen haplotypes (5).
In addition to genes of the MHC,
experimental evidence shows clearly that non-
MHC genes are involved in determining sus-
ceptibility to autoimmune diseases (6).
Among the non-MHC genes that may be
implicated are the immunoglobulin and T-cell
receptor variable region genes, inherited differ-
ences in the ontogeny of the thymus, and
genetic traits that influence the production of
cytokines and related immunologic mediators.
The best method to assess the importance
ofgenetic factors in determining susceptibil-
ity to autoimmune disease in humans is based
on comparisons of monozygotic and dizy-
gotic twins. In virtually every instance stud-
ied, the concurrence rate of monozygotic
twins ranges from 15 to 50%, whereas dizy-
gotic twins show little or no difference from
other siblings (6). In broad terms, therefore,
these data suggest that at least halfofthe sus-
ceptibility to autoimmune disease resides in
nonheritable, epigenetic factors. These factors
may include various forms ofgenetic reassort-
ment, somatic mutation, or other stochastic
events. It seems likely, however, that the
greater proportion ofthe remaining suscepti-
bility is due to environmental agents (7).
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Among the environmental agents
implicated in the induction ofautoimmune
disease, infectious organisms have historically
been the most prominent (8). There is, for
example, convincing epidemiologic evidence
that pharyngitis due to the beta hemolytic
streptococcus is a precipitating factor for
rheumatic heart disease. It is widely assumed
that this association is based on some form of
molecular mimicry between the microorgan-
ism and the initiating autoantigen in the
heart tissue ofthe host. However, at present,
few, ifany, clear-cut examples can be cited for
this form of molecular mimicry causing
human autoimmune disease (9).
Among the environmental agents known
to act as environmental triggers of human
autoimmune disease, the best established are
drugs (10). Drug-induced autoimmune
hemolytic anemia, thrombocytopenia, neu-
tropenia, and systemic lupus erythematosus
are well-established instances of external
agents that initiate a pathogenic autoimmune
response in susceptible hosts. When consider-
ing environmental agents, such as dietary
components and pollutants, evidence for an
association with autoimmune disease is more
problematic. There is, moreover, very little
understanding ofbiologic mechanisms by
which environmental agents can serve as the
triggers for autoimmune disease. Among
foodstuffs, excessive iodine intake has been the
best-studied example ofa factor that increases
the riskofautoimmune disease (11).
Iodine as an Environmental
Trigger ofAutoimmune
Thyroiditis
The introduction of dietary iodine as a
public health measure in the early twentieth
century eliminated endemic goiter in the
United States but may have spawned another
set ofproblems (12). The incidence ofauto-
immune thyroiditis is increasing concomi-
tantly with the progressively increasing
iodine content in theAmerican diet (13-15).
Sources ofdietary iodine include food and
food additives (kelp and seaweed, iodinated
salt, iodine additives to bread, flour, preserva-
tives, and red coloring), therapeutics (amio-
darone, vitamins, Lugol's iodine, etc.),
topical antiseptics, and contrast dyes. In
addition to the epidemiologic evidence, dini-
cal studies have suggested a relationship of
elevated iodine intake in autoimmune thy-
roid diseases (16-19). The effects ofhigh
iodine uptake, however, are observed only in
genetically susceptible individuals (20).
Conversely, in at least one clinical study,
restriction of dietary iodine reversed
hypothyroidism in 12 of22 patients. When
seven ofthe patients with reversed hypothy-
roidism were re-fed iodine, all of them
became hypothyroid again (21).
Many mechanisms have been suggested
to explain the association of iodine intake
with autoimmune thyroiditis (22). They
include damage by degeneration offree radi-
cals, direct injury to thymocytes, and phar-
macologic effects by inhibiting the sodium
iodine pump. Studies in our own laboratories
have strongly implicated a role of iodine in
promoting thyroid autoimmunity by
enhancing the autoimmunogenic properties
ofthyroglobulin (23,24).
Thyroglobulin, a major protein constituent
of the thyroid gland, is a highly conserved
protein among different mammalian species.
It serves as a biochemical storage form ofthe
circulating thyroid hormone thyroxine. It is
a homodimer, each chain comprising 2,748
amino acids, ofwhich 67 are tyrosines. Only
four ofthe tyrosines per chain, however, are
believed to play a role in the generation of
thyroxine (25). These four tyrosines have
high affinity for iodine. Early iodination evi-
dently takes place at these specific sites and
in a particular sequence (26,27). However,
many other tyrosyl sites are available for
storage ofiodine. The affinity ofthese other
tyrosyl residues varies considerably according
to their accessibility, neighboring groups,
and ionization constants. With increasing
degrees ofiodination, modifications in struc-
ture may occur that change the properties of
thyroglobulin and lead to new molecular
forms and to changes in stereochemical
shape (28,29). Increased binding ofiodine
to tyrosyl residues enhances the stability of
thyroglobulin and reduces its susceptibility
to the proteolytic cathepsins ofthe thyroid
(30). Increased iodination ofthyroglobulin
can thus heighten its autoimmunogenic
potential by changes in antigen processing,
alterations in stereochemical shape, produc-
tion ofnovel iodine-containing determinants,
or appearance ofcryptic epitopes.
Iodine Is Requiredfor Human
T-Cell Recognition
ofThyroglobulin
The important role of iodine in conferring
antigenicity on thyroglobulin was first
demonstrated by Roitt and Cooke (31). They
found that murine thyroglobulin-reactive
T cells proliferated with a human thyroglobu-
lin, depending upon the degree ofiodination
of the molecule. In order to validate the
studies in humans, we developed a thyroglob-
ulin-specific proliferation assay, using human
peripheral blood lymphocytes (32). T cells
from four offive patientswith chronic lympho-
cytic thyroiditis showed significant proliferation
with normal human thyroglobulin. Three of
five control samples from euthyroid individuals
also provided evidence ofproliferation but
significantly less than found in the patients
with thyroiditis. These findings suggest that
many normal humans have T cells reactive
with human thyroglobulin. In contrast, none
of the human T cells gave any measurable
proliferation in response to preparations of
thyroglobulin that contained no detectable
iodine even after addition ofinterleukin-2 to
increase the sensitivity ofthe assay procedure.
The essential role ofiodine was established
when the iodine-free thyroglobulin was iodi-
nated in vitro. It then produced a significant
proliferative response with both patient and
control lymphocytes, comparable in magni-
tude to that found with naturally iodinated
thyroglobulin. Our results demonstrate that
iodinated thyroglobulin is required for its
recognition byhuman T cells.
Effects of lodination on the
Immunoreactivity of Human
Thyroglobulin
We have considered two possibilities to
account for the increased antigenicity ofiodi-
nated thyroglobulin. First, iodination may
alter the stereochemical configuration ofthy-
roglobulin, thereby affecting the manner by
which it is processed and presented to T cells.
The second possibility is that iodine creates a
novel epitope by its presence in a particular
antigenic determinant. These two possibilities
were investigated using a panel of murine
monoclonal antibodies to human thyroglobu-
lin. These antibodies were carefully evaluated
by competitive inhibition test to delineate the
particular epitopes that they bound (33).
Some ofthe monoclonal antibodies reacted
with sites on thyroglobulin that were widely
shared among thyroglobulins of different
species and accounted for the extensive cross-
reactivity ofthis molecule. They represent the
most conserved portions of thyroglobulin
and, in many cases, are associated with its
physiologic function because they contain
thyroxine. Other monoclonals reacted with
sites that were relatively specific for the
human antigen. These sites were the same
ones recognized by antibodies from patients
with autoimmune thyroid disease (34). These
monoclonalswere not inhibited competitively
bythyroxine.
Detailed analysis demonstrated that
iodinated thyroglobulin differs from non-
iodinated thyroglobulin in its reactivity with
this panel ofmonoclonals and indicated a
loss of some epitopes and gain of others
(35). Thus, the insertion of iodine induces
significant stereochemical changes in the
thyroglobulin molecule, resulting in changes
in its immunoreactivity.
One of the monoclonals used in the
study was particularly valuable because it
reacted with iodinated thyroglobulin but
failed to react with the noniodinated mole-
cule. Moreover, its reaction with non-
iodinated thyroglobulin was restored when
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thyroglobulin was iodinated artificially
in vitro. The fine specificity ofthis antibody
was assessed using a series of iodinated thy-
ronines and tyrosines (36). Briefly, it was
found that the greatest affinity in terms of
competitive inhibition was produced by
3',5',3,5-tetraiodothyronine or thyroxine.
Significantly less binding was produced with
3,5',5-triiodothyronine, and even less by
reverse triiodothyronine, 3,3',5'-triiodothyro-
nine. Not only the number but the position
ofthe iodine substitutions on thyronine deter-
mines its binding affinity. Diiodothyronine
showed very little binding and none was
measured with noniodinated thyronine.
Thus, iodine is capable of producing a
unique epitope recognized by this mono-
clonal antibody. We suggest that the human
T cell may recognize a similar iodine-
containing antigenic determinant.
The NOD-H2h4 Mouse: A New
Model forthe Study ofthe
Role of Iodine in Autoimmune
Thyroiditis
The nonobese diabetic (NOD) mouse is
widely used as a model for type 1 diabetes
mellitus in humans. The disease in these mice
shares many features with human diabetes,
including insulitis, islet cell antibodies, and
genetic susceptibility conferred by both
MHC and non-MHC genes. The NOD
mouse expresses a unique class II MHC
molecule, I-A97. Dr. Linda Wicker at Merck
Laboratories created a series ofcongenics in
which the class II MHC region was replaced
by the MHC of other mouse strains
[described in Weatherall et al. (37)]. One of
these strains, designated NOD-H2h4, was
produced by crossing NOD with B1O.A(4R),
an H-2k mouse. None of these mice devel-
oped diabetes. An unexpected finding was a
high incidence ofspontaneous thyroiditis in
the NOD-H2h4 strain not found in either of
the parental strains. Furthermore, the inci-
dence ofthyroiditis rose when iodine was
added to the diet. Ifthe genetic predisposition
is present, therefore, an elevated intake of
iodine can tip the scales toward greater T-cell
stimulation and progression to thyroid disease.
To investigate the parameters of this
unique model ofa diet-induced autoimmune
disease in a genetically susceptible strain, we
added varying doses ofiodine to the drinking
water ofNOD-H2h4 congenic mice 8 weeks
of age and measured the prevalence ofthy-
roiditis. The prevalence ofdisease increased
with the dose and duration offeeding, lead-
ing to a maximum prevalence of> 90%.
The production of thyroid-specific
antibodies was followed over time (38). The
level ofantibodies to thyroglobulin paralleled
the increasing prevalence ofdisease. We were
unable to detect antibodies to a second
thyroid antigen, thyroperoxidase, and no
direct correlation could be demonstrated
between the lesion grade and the level of
thyroglobulin-specific antibody. However,
when we examined the individual isotypes of
thyroglobulin-specific antibodies, we found a
significant correlation between the presence
ofthyroglobulin-specific IgG2b antibody and
the occurrence ofthyroiditis.
These results strongly implicate the
pathogenic role ofthyroglobulin in this dis-
ease. In addition to the investigations ofthy-
roglobulin-specific antibody, adoptive
transfer experiments were conducted with
spleen cells from iodine-fed donor NOD-
H2h4 mice to younger recipients (39). These
younger animals had a very low incidence of
thyroiditis. When given spleen cells from
iodine-fed donors, however, the incidence of
disease increased significantly, illustrating
that the disease can be transferred by adop-
tive immunity. The relative importance of
cell-mediated and antibody-mediated
immune responses has not yet been defined
in this new mouse model.
To evaluate the reactivity of T cells to
murine thyroglobulin, NOD-H2h4 mice were
compared with three other strains. We found
that spleen cells ofNOD~H2h4 mice had an
innate ability to react with murine and
human thyroglobulin compared with the
three other strains tested. Moreover, follow-
ing treatment with iodine, the innate prolifer-
ation of the NOD-H2h4 to thyroglobulin
increased to more than double that of the
noniodinated treated animals.
In another series of experiments, we
evaluated the effects ofspecific pathogen-
free (SPF) and non-SPF conditions on
autoantibody production and disease
development. Iodine treatment under
non-SPF conditions resulted in a high
prevalence and greater severity of thy-
roiditis (40). The appearance of thy-
roglobulin-specific IgG2b was also
frequent in the non-SPF iodine-treated
group, corresponding with the greater
incidence of thyroid lesions. This finding
contrasts with the situation in conven-
tional NOD animals, which develop dia-
betes primarily under SPF conditions.
In our opinion, this new mouse model
will be ofgreat value in elucidating the bio-
logic mechanisms bywhich an environmental
agent can induce autoimmune disease in a
susceptible host.
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